Andere talen Acumen Pharmaceuticals, Inc.

Aandelen

ABOS

US00509G2093

Geschatte realtime Cboe BZX Andere beurzen 20:57:41 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,33 ^USD	+3,42%		+3,14%	-14,58%

04/04	Acumen Pharmaceuticals sluit overeenkomst met Lonza voor productie van geneesmiddel tegen Alzheimer	MT
04/04	Lonza sluit productieovereenkomst voor Acumen's kandidaat-geneesmiddel voor de ziekte van Alzheimer	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting	17/04
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting	16/04
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04/04
Borsa svizzera chiude in rialzo, SMI +0,64%	04/04
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04/04
Lonza produziert Arzneimittelkandidaten von Acumen Pharmaceuticals	04/04
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease	04/04
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04/04
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	27/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights	26/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting	21/03
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting	21/03
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024	19/03
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024	19/03
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days	12/03
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days	12/03
Acumen Pharmaceuticals : ADPD 2024 CSF Biomarker Presentation	08/03
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting	08/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Acumen Pharmaceuticals, Inc.

Aandelen

ABOS

US00509G2093

Andere talen

Filters